Vutrisiran Shows Sustained Clinical Benefit in East Asian ATTR-PN Vutrisiran produced consistent improvements in neuropathy impairment, quality of life, walking speed, and disability in patients with ATTR-PN, per a recent study.

East Asian patients with ATTR-PN treated with #Vutrisiran achieve meaningful improvements in neuropathy impairment, quality of life, walking speed, and disability despite higher baseline disease burden and prior #Tafamidis use.

Read more: https://bit.ly/4tgDp38

#RareDisease #ATTRPN #NeuroSky

NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance - PharmaTimes First long-acting therapy with three-monthly dosing to target root cause of cardiac disease

#AlnylamUK #NICE #vutrisiran #Amvuttra #ATTRCM #NICEfinaldraftguidance #transthyretinamyloidosiswithcardiomyopathy #hereditaryATTR #stage1polyneuropathy #stage2polyneuropathy #NICEfinalguidance #HELIOSBstudy #cardiovascular #stiffheartdisease #AnnaTomlinson #CardiomyopathyUK
zurl.co/0yB9A

In a trial of 150 patients with ATTR-CM, vutrisiran reduced deaths and recurrent CV events after 36 months compared to placebo. A game-changer for this fatal disease! #ATTR #Vutrisiran PMID:39213194, N Engl J Med 2024